Journal
ARCHIVES OF INTERNAL MEDICINE
Volume 171, Issue 21, Pages 1901-1907Publisher
AMER MEDICAL ASSOC
DOI: 10.1001/archinternmed.2011.492
Keywords
-
Categories
Funding
- National Institutes of Health
- Pfizer Pharmaceuticals
- Abbott Pharmaceuticals
- Aradigm
- American Academy of Addiction Psychiatry
- American Psychiatric Association
- American Psychiatric Institute for Research and Education
- Cambridge Hospital
- Dartmouth College
- Dartmouth-Hitchcock
- Dean Foundation
- DLA Piper
- EPI-Q
- European Respiratory Society
- Evotec
- Free and Clear
- GlaxoSmithKline
- Golin Harris
- Healthwise
- Integrated Communication
- Invivodata
- Maine Health
- McGill University Medical School
- McNeil Pharmaceuticals
- Novartis Pharmaceuticals
- Oglivy Health PR
- Ottawa Heart Institute
- Pinney Associates
- Propagate Pharmaceuticals
- Reckner Associates
- Scientia
- University of Arkansas for Medical Sciences
- University of California-San Francisco
- University of Wisconsin
- Wolters Publishing
- National Institute on Drug Abuse [R01DA021619, K23DA020482, K05DA000490, K12DA000357]
Ask authors/readers for more resources
Background: Rates of smoking cessation have not changed in a decade, accentuating the need for novel approaches to prompt quit attempts. Methods: Within a nationwide randomized clinical trial (N=849) to induce further quit attempts and cessation, smokers currently unmotivated to quit were randomized to a practice quit attempt (PQA) alone or to nicotine replacement therapy (hereafter referred to as nicotine therapy), sampling within the context of a PQA. Following a 6-week intervention period, participants were followed up for 6 months to assess outcomes. The PQA intervention was designed to increase motivation, confidence, and coping skills. The combination of a PQA plus nicotine therapy sampling added samples of nicotine lozenges to enhance attitudes toward pharmacotherapy and to promote the use of additional cessation resources. Primary outcomes included the incidence of any ever occurring self-defined quit attempt and 24-hour quit attempt. Secondary measures included 7-day point prevalence abstinence at any time during the study (ie, floating abstinence) and at the final follow-up assessment. Results: Compared with PQA intervention, nicotine therapy sampling was associated with a significantly higher incidence of any quit attempt (49% vs 40%; relative risk [RR], 1.2; 95% CI, 1.1-1.4) and any 24-hour quit attempt (43% vs 34%; 1.3; 1.1-1.5). Nicotine therapy sampling was marginally more likely to promote floating abstinence (19% vs 15%; RR, 1.3; 95% CI, 1.0-1.7); 6-month point prevalence abstinence rates were no different between groups (16% vs 14%; 1.2; 0.9-1.6). Conclusion: Nicotine therapy sampling during a PQA represents a novel strategy to motivate smokers to make a quit attempt.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available